ClinicalTrials.gg
RecruitingNCT06049186Updated Sep 22, 2023

CRD vs. Met in Patients With Obese PCOS Infertility

An interventional study of CRD and Metformin in Polycystic Ovary Syndrome, sponsored by Shanghai First Maternity and Infant Hospital. Recruiting at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Shanghai First Maternity and Infant Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Polycystic Ovary Syndrome with a site in China — 29 open to participants now, 33 under way, none of them phase 3. Polycystic Ovary Syndrome · China.

Planned enrollment
11th of 86
406 · median 100
Started
2023
with 8 others
No phase
51 of 107
11 open now
Primary completion
2026-01
later than 12 of 32 live
Registered
75th of 107
by date

Among the 107 studies in Polycystic Ovary Syndrome with a site in China, this one is the 11th largest by planned enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2023, is one of 51 with no phase, reaches primary completion later than 12 of the 32 other live ones, and was the 75th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

29 of the 107 studies in Polycystic Ovary Syndrome with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Polycystic Ovary Syndrome with a site in China, or all of them as a file.
02

Study summary

Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disease and a major cause of anovulatory infertility in reproductive-aged women. From 2010 to 2020, it was found that the prevalence of PCOS in reproductive-aged women in China reached 7.8%, an increase of 65% over 10 years ago. Many of them are overweight or obese. Weight loss including diet modifications can significantly reduce reproductive and metabolic disorders of PCOS and is recommended as a first step in the treatment of overweight or obese women with PCOS. Many weight loss programs have been proposed, including calorie-restriction diet (CRD) intervention. Whether CRD intervention prior to ovulation induction therapy could improve live birth rates in overweight/obese PCOS women has not been illustrated.

Read the detailed description

Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disease and a major cause of anovulatory infertility in reproductive-aged women. Rotterdam criteria state the definition of PCOS is that women must present with two of the following three signs/symptoms-hyperandrogenism, chronic anovulation/oligomenorrhea, and polycystic ovaries-in the absence of other diseases that promote these symptoms. From 2010 to 2020, it was found that the prevalence of PCOS in reproductive-aged women in China reached 7.8%, an increase of 65% over 10 years ago. Many of them are overweight or obese. Weight loss including diet modifications can significantly reduce reproductive and metabolic disorders of PCOS and is recommended as a first step in the treatment of overweight or obese women with PCOS. Many weight loss programs have been proposed, including calorie-restriction diet (CRD) intervention. Whether CRD intervention prior to ovulation induction therapy could improve live birth rates in overweight/obese PCOS women has not been illustrated. This research is aimed to evaluate whether CRD intervention prior to ovulation induction could promote reproductive health in overweight or obese PCOS women with fertility requirements and provide an evidence-based nutrition advice for clinical practice.

03

Conditions studied

  • Polycystic Ovary Syndrome
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. a diagnosis of polycystic ovary syndrome (PCOS) based on the Rotterdam diagnostic criteria;
  2. age 20-35 years old;
  3. a body-mass index over 23;
  4. have requirements for fertility.

Exclusion criteria

Exclusion Criteria:

  1. acute or chronic viral hepatitis;
  2. serious liver dysfunction or chronic kidney disease;
  3. serious cardiovascular or cerebrovascular disease;
  4. patients with a history of acute/chronic infection, severe cardiovascular and cerebrovascular diseases, and malignant tumors;
  5. have drugs for PCOS such as and anti-androgen drugs (spironolactone, cyproterone acetate, flutamide, etc.) within 3 months;
  6. congenital or secondary uterine abnormalities;
  7. use of medications that affect weight or energy balance such as Metformin within 3 months;
  8. undergoing weight loss treatment (weight change greater than 5% in the past 3 months) or have a history of gastrointestinal surgery;
  9. tubal obstruction;
  10. the total number of motile sperm of male partner is less than 10 million;
  11. any other situations that might affect the trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
406 participants (estimated)

Study arms

  • Experimental
    CRD group

    Patients in the calorie-restricted diet (CRD) group will have strict calorie-restriction diets for 8 weeks and then weight stability for 4 weeks.

    Behavioral: CRD

  • Active comparator
    Control group

    Patients in the control group will receive regular diets and metformin 1500 mg daily for 12 weeks. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.

    Drug: Metformin

Interventions

  • BehavioralCRD

    During the initial 8 weeks of the trial, polycystic ovary syndrome (PCOS) patients are instructed to follow a diet of 1200 to 1500 kcal per day supervised by dietitians. The CRD includes a combination of 40 to 55% of calories from carbohydrates, 15 to 20% from protein, and 20 to 30% from fat; this regimen represented approximately 75% of the participants' daily caloric intake at baseline. All the participants receive dietary counseling daily during the trial.

    Also known as: Calorie-restricted diet

  • After randomization, patients entering the metformin group will be given 1500 mg daily (bid/tid) metformin and regular diets as control. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.

    Also known as: Metformin treatment

06

What researchers measure

Primary outcomes

  1. Live birth during the period of ovulation induction

    Live birth will be defined as the delivery of one or more living infants (≥22 week's gestation or birth weight more than 500g). The outcome could be assessed by clinical data and clinical diagnosis.

    Time frame: 18 months

Secondary outcomes

  1. Fasting blood glucose (FBG)

    A laboratory test that determines the level of glucose in the blood after an overnight fast, used especially to diagnose diabetes and prediabetes. The normal interval is 3.9-6.1mmol/L. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  2. Fasting insulin (FINS)

    The level of insulin in the blood during fasting (usually in the morning when fasting). The normal interval is 5\~20 μIU. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  3. Oral glucose tolerance test (OGTT)

    An oral glucose tolerance test (OGTT) is a diagnostic tool used to evaluate how an individual's body metabolizes sugar. Often used to diagnose diabetic conditions, an oral glucose tolerance test requires minimal preparatory measures and may be safely administered during pregnancy. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  4. Insulin release test (IRT)

    Quantitative oral glucose during fasting increases blood glucose and stimulates pancreatic β cells to release insulin. By measuring plasma insulin levels during fasting and 0.5h, 1h, 2h, and 3h after taking sugar, we can understand the secretion and reserve function of pancreatic β cells, which is also helpful for the classification of diabetes mellitus and guide treatment. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  5. Blood lipid

    Lipid related indicators include cholesterol, triglycerides. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  6. Kidney function index

    Blood tests that are included in the kidney function test include measuring for creatinine and blood urea nitrogen (BUN). The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  7. Liver function index

    Liver function index includes alanine aminotransferase (ALT), alkaline phosphatase (ALP) . The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  8. Free testosterone (FT)

    The average serum testosterone concentration is 0.43ng/ml, the high limit is 0.68ng/ml, if more than 0.7ng/m1 (equal to 2.44nmol/L), it is called hypertestosterone, or hyperandrogenemia. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  9. Total testosterone (TT)

    The normal range of female testosterone is 0.1-0.75ng /ml, testosterone is the main sex hormone of the human body, men and women have secretion, male testosterone secretion is 20-30 times the amount of female testosterone secretion, it is very important to maintain the second sexual characteristics, bone and muscle strength. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  10. Sex Hormone Binding Globulin (SHBG)

    A globulin synthesized by liver cells that can bind sex hormones, also known as testosterone - estrogen binding globulin or steroidal binding protein, is an important carrier of sex hormones, which can have an important impact on the regulation of sex hormone levels and bioavailability in the body. Clinical detection of SHBG level can provide scientific reference value for disease detection and judgment. The normal interval is 20-130nmol/L for women. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  11. Liver transient elastography(TE)

    TE may be used to monitor disease progression or regression via serial measurements and to guide further management including treatment. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  12. Weight

    Unit: kilogram (kg). The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  13. Height

    Unit: meter (m). The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  14. Body Mass Index (BMI)

    BMI = weight (in kg)/ height\^2 (in m\^2).

    Time frame: Baseline period and 3 months

  15. Waist circumference

    Unit: centimeter (cm). The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  16. Body fat

    Body fat is measured by body fat scale. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  17. Lean body weight

    Lean body weight refers to the total weight of organs, bones, and muscles. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  18. Blood pressure (BP)

    Blood pressure is a measurement of the force of blood against the arterial walls when the heart pumps. The pressure is measured in millimeters of mercury (mmHg) and is expressed as two numbers. For example, the optimal BP for an adult is 120 over 80, or 120/80. A pressure reading of 120 over 80 or lower is considered healthy. If the systolic number ranges above 120 to 139 or the diastolic number ranges above 80 to 89, a person is considered to have pre-hypertension. Systolic readings from 140 to 159 or diastolic readings from 90 to 99 are classified as stage 1 hypertension. Systolic measurements of 160 or above or diastolic measurements of 100 or above indicate the severe condition of stage 2 hypertension. The outcome could be assessed by clinical data and clinical test.

    Time frame: Baseline period and 3 months

  19. Hospital Anxiety and Depression Scale (HADS)

    The purpose of the HADS was to screen for clinically significant anxiety and depressive symptoms in medically ill patients. Content The HADS-A includes specific items that assess generalized anxiety including tension, worry, fear, panic, difficulties in relaxing, and restlessness. The total score for the HADS-A can range from 0 to 21. The following guidelines are recommended for the interpretation of scores: 0-7 for normal or no anxiety, 8-10 for mild anxiety, 11-14 for moderate anxiety, and 12-21 for severe anxiety.

    Time frame: Baseline period and 3 months

  20. Biochemical pregnancy

    A pregnancy diagnosed only by the detection of beta hCG in serum or urine. The outcome could be assessed by clinical data and clinical diagnosis.

    Time frame: 8 months

  21. Ectopic pregnancy

    Ectopic pregnancy (EP) is defined as the implantation and development of a fertilized ovum anywhere outside of the uterine cavity. The outcome could be assessed by clinical data and clinical diagnosis.

    Time frame: 8 months

  22. Pregnancy failure

    Pregnancy failure, otherwise termed as pregnancy loss or miscarriage, can occur at different stages during this process and many different pathophysiological mechanisms may be implicated. The outcome could be assessed by clinical data and clinical diagnosis.

    Time frame: 8 months

  23. Birth weight

    Macrosomia is defined in a newborn as a birth weight more than two standard deviations above the mean percentile for gestational age, \>90th percentile weight for gestational age, or a birth weight greater than 4000g at term. The outcome could be assessed by clinical data and clinical diagnosis.

    Time frame: 18 months

  24. Neonatal complications

    Neonatal complications include intraventricular hemorrhage, necrotizing enterocolitis, respiratory distress syndrome, bronchopulmonary dysplasia, jaundice. The outcome could be assessed by clinical data and clinical diagnosis.

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yang R, Li Q, Zhou Z, Qian W, Zhang J, Wu Z, Jin L, Wu X, Zhang C, Zheng B, Tan J, Hao G, Li S, Tian T, Hao Y, Zheng D, Wang Y, Norman RJ, Li R, Liu P, Qiao J. Changes in the prevalence of polycystic ovary syndrome in China over the past decade. Lancet Reg Health West Pac. 2022 May 31;25:100494. doi: 10.1016/j.lanwpc.2022.100494. eCollection 2022 Aug. PubMed 35669932 ↗
  • Lie Fong S, Douma A, Verhaeghe J. Implementing the international evidence-based guideline of assessment and management of polycystic ovary syndrome (PCOS): how to achieve weight loss in overweight and obese women with PCOS? J Gynecol Obstet Hum Reprod. 2021 Jun;50(6):101894. doi: 10.1016/j.jogoh.2020.101894. Epub 2020 Aug 16. PubMed 32814159 ↗
  • Shahid R, Iahtisham-Ul-Haq, Mahnoor, Awan KA, Iqbal MJ, Munir H, Saeed I. Diet and lifestyle modifications for effective management of polycystic ovarian syndrome (PCOS). J Food Biochem. 2022 Jul;46(7):e14117. doi: 10.1111/jfbc.14117. Epub 2022 Feb 24. PubMed 35199348 ↗
  • Szczuko M, Kikut J, Szczuko U, Szydlowska I, Nawrocka-Rutkowska J, Zietek M, Verbanac D, Saso L. Nutrition Strategy and Life Style in Polycystic Ovary Syndrome-Narrative Review. Nutrients. 2021 Jul 18;13(7):2452. doi: 10.3390/nu13072452. PubMed 34371961 ↗
  • Paoli A, Mancin L, Giacona MC, Bianco A, Caprio M. Effects of a ketogenic diet in overweight women with polycystic ovary syndrome. J Transl Med. 2020 Feb 27;18(1):104. doi: 10.1186/s12967-020-02277-0. PubMed 32103756 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Jan 2026, 27 months later.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 27 months is above that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Sep 22, 2023
StartEst.
Sep 15, 2023
Primary completionEst.
Jan 1, 2026
CompletionEst.
Mar 31, 2026
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06049186
Lead sponsor
Shanghai First Maternity and Infant Hospital
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Sep 15, 2023 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Sep 22, 2023

Study contacts

Miaoxin Chen, Dr
Contact
chenmiaoxin@51mch.com
20261000
Miaoxin Chen, Dr
study chair · Shanghai First Maternity and Infant Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion